Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats

Diabetologia

Volumn 58, Issue 12, 2015, Pages 2885-2898

  Rafiq, Kazi ^a   Fujisawa, Yoshihide ^a   Sherajee, Shamshad J ^a   Rahman, Asadur ^a   Sufiun, Abu ^a   Kobori, Hiroyuki ^a   Koepsell, Hermann ^b   Mogi, Masaki ^c   Horiuchi, Masatsugu ^c   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure; Glucose metabolism; Insulin resistance; Renal sympathetic denervation (RDX); Sglt2; Slc5a2; Sodium glucose cotransporter 2; Type 2 diabetes

Indexed keywords

GLUCOSE TRANSPORTER; NORADRENALIN; SODIUM GLUCOSE COTRANSPORTER 2; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSURIA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; KIDNEY DENERVATION; KIDNEY METABOLISM; KIDNEY NERVE; KIDNEY PARENCHYMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RESISTANT HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPATHETIC NERVE; ADRENERGIC SYSTEM; ANIMAL; BLOOD; BLOOD PRESSURE; GLUCOSE CLAMP TECHNIQUE; IMPAIRED GLUCOSE TOLERANCE; INNERVATION; KIDNEY; METABOLISM; NEPHRECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; SYMPATHECTOMY;

ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLYCOSURIA; HUMANS; KIDNEY; NEPHRECTOMY; NOREPINEPHRINE; PREDIABETIC STATE; RATS; RATS, INBRED OLETF; SODIUM-GLUCOSE TRANSPORTER 2; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84946491938     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3771-9     Document Type: Article

References (58)

1. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E (2006) Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48:787–796
2. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP (2010) Sympathetic nervous activation in obesity and the metabolic syndrome—causes, consequences and therapeutic implications. Pharmacol Ther 126:159–172
3. Scherrer U, Sartori C (1997) Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 96:4104–4113
4. Mancia G, Bousquet P, Elghozi JL et al (2007) The sympathetic nervous system and the metabolic syndrome. J Hypertens 25:909–920
5. Linz D, Hohl M, Schutze J et al (2015) Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of renal sympathetic innervation. Am J Hypertens 28:256–265
6. DiBona GF (2005) Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Com Physiol 289:R633–R641
7. Esler M (2010) The 2009 Carl Ludwig lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (1985) 108:227–237
8. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA (2003) Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108:3097–3101
9. Vollenweider P, Tappy L, Randin D et al (1993) Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 92:147–154
10. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:615–621
11. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA (2012) Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126:2976–2982
12. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903–1909
13. Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281
14. Brandt MC, Mahfoud F, Reda S et al (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59:901–909
15. Rafiq K, Noma T, Fujisawa Y et al (2012) Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125:1402–1413
16. Bhatt DL, Kandzari DE, O'Neill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401
17. Mahfoud F, Schlaich M, Kindermann I et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123:1940–1946
18. Witkowski A, Prejbisz A, Florczak E et al (2011) Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58:559–565
19. Schlaich MP, Straznicky N, Grima M et al (2011) Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 29:991–996
20. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:1422–1428
21. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H (1997) Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension 29:728–735
22. Recordati G, Genovesi S, Cerati D (1982) Renorenal reflexes in the rat elicited upon stimulation of renal chemoreceptors. J Auton Nerv Syst 6:127–142
23. Recordati G, Genovesi S, Cerati D, di Cintio R (1980) Reno-renal and reno-adrenal reflexes in the rat. Clin Sci (Lond) 59(Suppl 6):S323–S325
24. Nakashima A, Matsuoka H, Yasukawa H et al (1996) Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chronic inhibition of nitric oxide synthesis. Nephron 73:34–40
25. Luippold G, Beilharz M, Muhlbauer B (2004) Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 19:342–347
26. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884–890
27. Rafiq K, Hitomi H, Nakano D, Ichihara A, Nishiyama A (2011) Possible involvement of the (pro)renin receptor-dependent system in the development of insulin resistance. Front Biosci (Schol Ed) 3:1478–1485
28. Kraegen EW, James DE, Bennett SP, Chisholm DJ (1983) In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am J Physiol 245:E1–E7
29. Ogihara T, Asano T, Ando K et al (2002) Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40:872–879
30. Prysyazhna O, Rudyk O, Eaton P (2012) Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med 18:286–290
31. Zhang YC, Bui JD, Shen L, Phillips MI (2000) Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation 101:682–688
32. Shiuchi T, Iwai M, Li HS et al (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43:1003–1010
33. Shiuchi T, Nakagami H, Iwai M et al (2001) Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. Endocrinology 142:608–612
34. Sudo M, Minokoshi Y, Shimazu T (1991) Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol 261:E298–E303
35. Rafiq K, Nakano D, Ihara G et al (2011) Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens 29:290–298
36. Sherajee SJ, Fujita Y, Rafiq K et al (2012) Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol 32:257–263
37. Sabolic I, Vrhovac I, Eror DB et al (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302:C1174–C1188
38. Masuo K, Mikami H, Ogihara T, Tuck ML (1997) Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 10:77–83
39. Grassi G, Dell'Oro R, Quarti-Trevano F et al (2005) Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48:1359–1365
40. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO (1993) Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21:618–623
41. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G (2004) Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 22:2363–2369
42. Wenzel RR, Spieker L, Qui S, Shaw S, Luscher TF, Noll G (1998) I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 32:1022–1027
43. Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, Steinberg MI (1999) Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 48:1093–1100
44. Krupicka J, Soucek M, Chroust K (2011) The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). Vnitr Lek 57:541–545
45. Prichard BN, Jager BA, Luszick JH et al (2002) Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 11:166–172
46. Helgeland A, Leren P, Foss OP, Hjermann I, Holme I, Lund-Larsen PG (1984) Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The Oslo study. Am J Med 76:802–805
47. William-Olsson T, Fellenius E, Bjorntorp P, Smith U (1979) Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand 205:201–206
48. Gudbjornsdottir S, Fowelin J, Elam M et al (1997) The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects. Euro J Clin Investig 27:29–35
49. Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298:1152–1157
50. Day JL (1975) The metabolic consequences of adrenergic blockade: a review. Metab Clin Exp 24:987–996
51. Lager I, Blohme G, Smith U (1979) Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet 1:458–462
52. Cersosimo E, Ajmal M, Naukam RJ, Molina PE, Abumrad NN (1997) Role of the kidney in plasma glucose regulation during hyperglycemia. Am J Physiol 272:E756–E761
53. Dominguez JH, Song B, Maianu L, Garvey WT, Qulali M (1994) Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am Soc Nephrol 5:S29–S36
54. Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–112
55. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733–794
56. Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Investig 93:397–404
57. Pajor AM, Hirayama BA, Wright EM (1992) Molecular evidence for two renal Na+/glucose cotransporters. Biochim Biophys Acta 1106:216–220
58. Nakagawa T, Hasegawa Y, Uekawa K et al (2013) Renal denervation prevents stroke and brain injury via attenuation of oxidative stress in hypertensive rats. J Am Heart Assoc 2:e000375